Barclays now sees two Fed cuts this year, says jumbo Fed cuts ’very unlikely’
Investing.com -- Liminatus Pharma Inc (NASDAQ:LIMN) stock jumped 26.5% after the preclinical-stage biopharmaceutical company announced it has engaged Digital Offering LLC to serve as its exclusive placement agent for a potential strategic capital raise.
The company, which focuses on developing targeted cancer immunotherapies, said the engagement supports its previously disclosed review of a digital asset treasury strategy. Liminatus is evaluating modern financial tools to strengthen its capital structure, with potential funding initiatives that may include convertible debentures, equity-linked securities, or other alternative instruments compliant with U.S. securities laws.
Digital Offering, a FINRA- and SEC-registered broker-dealer, will assist Liminatus in sourcing institutional and digital asset-focused investors and structuring a compliant financing solution.
"At Liminatus, our core mission is advancing transformative immunotherapies for cancer," said Chris Kim, CEO of Liminatus. "As we work toward that goal, we are also taking proactive steps to strengthen our capital strategy. Partnering with Digital Offering allows us to explore strategic funding opportunities—both in traditional markets and the evolving digital asset landscape—with discipline and foresight."
The company emphasized that no financing transaction has been finalized, and any potential capital transaction would remain subject to Board approval and full regulatory compliance. The announcement does not constitute an offer to sell or solicitation of an offer to buy securities in any jurisdiction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.